Pharmion Purchases Cabrellis, US Developer of Amrubicin

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 12
Volume 15
Issue 12

Pharmion Corporation has acquired Cabrellis Pharmaceuticals and gained US and European rights to amrubicin, a third-generation synthetic anthracycline currently in phase II trials for small-cell lung cancer in North America and Europe.

BOULDER, Colorado—Pharmion Corporation has acquired Cabrellis Pharmaceuticals and gained US and European rights to amrubicin, a third-generation synthetic anthracycline currently in phase II trials for small-cell lung cancer in North America and Europe.

Articles in this issue
Best Rx Most Cost-Effective: RTOG
Grape Seed Found to Be a Natural Aromatase Inhibitor
Drug Combination Prevents ER-Negative Tumors in Mice
Democrats' Agenda May Stifle Efforts for More Ca Funding
No Loss of Efficacy With Synchronous Chemotherapy/ESP
'Share Care' Difficult for Ca Survivors and Their Oncologists
Biomarkers Panel Promising for Detecting Pancreatic Ca
Preop Avastin/Tarceva in RCC
Aggressive Hyperglycemia Control Essential in Patients With Diabetes Hospitalized for Treatment of Cancer
Reovirus Agent Shows Activity in Phase I Trial
Eisai Acquires Four Oncology- Related Products From Ligand
Genetic Brain Tumor Study Gets $11 Million NCI Grant
Postoperative RT Boosts Survival in N2 Lung Ca Patients
ACCC Weighs in on Critical Cancer Care Issues:
Treatment Strategies Needed for Subpopulations of Colorectal Cancer Patients

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Video 4 - "Frontline Treatment for EGFR-Mutated Lung Cancer"
Related Content
Findings from a multicenter cohort study support screening adherence as a key lung cancer screening quality metric.

Lung Cancer Screening Adherence Decreases Across Subsequent Testing

Russ Conroy
April 24th 2025
Article

Findings from a multicenter cohort study support screening adherence as a key lung cancer screening quality metric.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).

TTFields Therapy Earns EU Approval in Metastatic Non–Small Cell Lung Cancer

Russ Conroy
April 23rd 2025
Article

Data from the phase 3 LUNAR trial support the Conformité Européenne Mark for tumor treating fields in metastatic non–small cell lung cancer.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

3 Things You Should Know About Unresectable NSCLC

3 Things You Should Know About Unresectable NSCLC

ONCOLOGY Staff
April 21st 2025
Article

In first-line, EGFR-mutated NSCLC, targeted therapies such as osimertinib or amivantamab plus lazertinib are recommended.

Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC

Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC

Tim Cortese
April 20th 2025
Article

A 5-year follow-up of the phase 3 EMPOWER-Lung 1 showed the greatest survival benefits in patients with NSCLC who have a PD-L1 expression of 90% or more.